Modulation of Gastrointestinal Mucus Properties with Ionic Liquids for Drug Delivery
Source abstract
Abstract
Abstract The mucus barrier lining the gastrointestinal tract poses a significant barrier to the oral delivery of macromolecular drugs. Successful approaches to overcoming this barrier have primarily focused on reducing drug and carrier interactions with mucus or disrupting the mucus layer directly. Choline‐based ionic liquids (ILs) such as choline geranate and choline glycolate (CGLY) have recently been shown to be effective in enhancing the intestinal absorption of macromolecules such as insulin and immunoglobulin (IgG), respectively. Herein, the use of choline‐based ILs as mucus‐modulating agents for safely improving drug penetration through mucus is described. Choline‐based ILs significantly increase the diffusion rates of cationic dextrans through mucin solution. Choline‐maleic acid (CMLC 2:1) enhances the diffusion of 4 kDa cationic dextran in mucin solution by more than fourfold when compared to phosphate‐buffered saline control. Choline‐based ILs also reduce mucus viscosity without significantly impacting the native mucus gel structure. In vitro studies in a mucus‐secreting coculture model with Caco‐2 and HT29MTX‐E12 cells further demonstrate the effectiveness of ILs in improving transport of cationic molecules in the presence of secreted mucus. This work demonstrates the potential for choline‐based ionic liquids to be used as nondestructive mucus‐modulating agents for enabling enhanced oral delivery of macromolecular drugs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Carbohydrate Chemistry and Synthesis · Glycosylation and Glycoproteins Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
Wyss Institute for Biologically Inspired Engineering Harvard University Boston MA 02115 USA
References (60)
Show source-provided references
1. 10.1111/bcpt.1234210.1111/bcpt.12342 ↗
2. 10.1016/j.tcb.2011.06.00210.1016/j.tcb.2011.06.002 ↗
3. 10.1016/j.addr.2008.09.00810.1016/j.addr.2008.09.008 ↗
4. 10.1016/j.addr.2008.09.01210.1016/j.addr.2008.09.012 ↗
5. 10.1016/j.addr.2008.11.00210.1016/j.addr.2008.11.002 ↗
6. 10.1074/jbc.M30902620010.1074/jbc.M309026200 ↗
7. 10.1016/j.biomaterials.2011.05.00810.1016/j.biomaterials.2011.05.008 ↗
8. 10.1016/j.ejpb.2015.01.02310.1016/j.ejpb.2015.01.023 ↗
9. 10.2217/nnm.13.2610.2217/nnm.13.26 ↗
10. 10.1016/S0006-3495(01)75844-410.1016/S0006-3495(01)75844-4 ↗
11. 10.1002/mabi.20100013710.1002/mabi.201000137 ↗
12. 10.1016/j.ijpharm.2006.02.05310.1016/j.ijpharm.2006.02.053 ↗
13. 10.1016/j.prrv.2007.02.00910.1016/j.prrv.2007.02.009 ↗
14. 10.1016/j.ejpb.2013.12.01210.1016/j.ejpb.2013.12.012 ↗
15. 10.1016/j.addr.2016.03.01110.1016/j.addr.2016.03.011 ↗
16. 10.1155/2018/283578710.1155/2018/2835787 ↗
17. 10.1073/pnas.172233811510.1073/pnas.1722338115 ↗
18. 10.1016/j.jconrel.2019.08.02910.1016/j.jconrel.2019.08.029 ↗
19. 10.1016/j.jconrel.2018.07.02910.1016/j.jconrel.2018.07.029 ↗
20. Peng K. · ACS Biomater. Sci. Eng. · 2020
21. 10.1016/j.jconrel.2020.07.03710.1016/j.jconrel.2020.07.037 ↗
22. 10.1016/j.jconrel.2020.03.01810.1016/j.jconrel.2020.03.018 ↗
23. 10.1039/C3CC48650H10.1039/C3CC48650H ↗
24. 10.1002/adfm.20200291210.1002/adfm.202002912 ↗
25. 10.1002/adma.20190110310.1002/adma.201901103 ↗
26. 10.1073/pnas.140399511110.1073/pnas.1403995111 ↗
27. 10.1164/ajrccm.162.5.990900910.1164/ajrccm.162.5.9909009 ↗
28. 10.1038/s41598-019-53933-510.1038/s41598-019-53933-5 ↗
29. 10.1038/s41598-020-77129-410.1038/s41598-020-77129-4 ↗
30. 10.1016/j.jconrel.2009.10.03010.1016/j.jconrel.2009.10.030 ↗
31. 10.1016/j.jnutbio.2008.05.00610.1016/j.jnutbio.2008.05.006 ↗
32. 10.1016/j.jconrel.2016.07.05110.1016/j.jconrel.2016.07.051 ↗
33. 10.1016/j.addr.2008.09.00610.1016/j.addr.2008.09.006 ↗
34. 10.1016/j.addr.2017.11.00110.1016/j.addr.2017.11.001 ↗
35. 10.1021/acs.molpharmaceut.7b0023610.1021/acs.molpharmaceut.7b00236 ↗
36. 10.1016/j.ijpharm.2017.09.01810.1016/j.ijpharm.2017.09.018 ↗
37. 10.1016/j.bpj.2010.01.01210.1016/j.bpj.2010.01.012 ↗
38. 10.1371/journal.pone.008238210.1371/journal.pone.0082382 ↗
39. 10.1021/acsbiomaterials.9b0024310.1021/acsbiomaterials.9b00243 ↗
40. 10.1152/ajplung.00180.201010.1152/ajplung.00180.2010 ↗
41. Fallingborg J. · Dan. Med. Bull. · 1999 · 46 · 183
42. 10.1016/S0168-3659(96)01586-610.1016/S0168-3659(96)01586-6 ↗
43. 10.1016/S0016-7061(98)00098-610.1016/S0016-7061(98)00098-6 ↗
44. 10.1038/s41598-020-65392-410.1038/s41598-020-65392-4 ↗
45. 10.1073/pnas.090343810610.1073/pnas.0903438106 ↗
46. 10.1093/nar/gky103310.1093/nar/gky1033 ↗
47. 10.1007/978-94-009-5883-810.1007/978-94-009-5883-8 ↗
48. 10.1093/nar/gkx108910.1093/nar/gkx1089 ↗
49. 10.1093/nar/gks106510.1093/nar/gks1065 ↗
50. 10.1093/nar/gkn81010.1093/nar/gkn810 ↗
51. 10.1093/nar/gkj06710.1093/nar/gkj067 ↗
52. 10.1093/nar/gkl92310.1093/nar/gkl923 ↗
53. 10.1039/c0cc03089a10.1039/c0cc03089a ↗
54. 10.1039/D0CP01431A10.1039/D0CP01431A ↗
55. 10.1039/b900201d10.1039/b900201d ↗
56. 10.1039/C8CS00325D10.1039/C8CS00325D ↗
57. 10.1021/acs.biomac.7b0080910.1021/acs.biomac.7b00809 ↗
58. 10.1136/gut.46.2.21810.1136/gut.46.2.218 ↗
59. 10.1042/CBI2009048110.1042/CBI20090481 ↗
60. 10.1097/TA.000000000000049910.1097/TA.0000000000000499 ↗